Pfizer Ups Bid to Compete with Novo Nordisk for Metsera in $10 Billion Obesity Drug Deal
Pfizer has increased its efforts to acquire Metsera, a U.S. biotech company focused on obesity drugs. The company recently removed some conditions from its takeover offer and is preparing to raise its bid, according to news reports and a letter Pfizer sent to a Delaware judge.
The battle for Metsera has intensified, with Danish pharmaceutical company Novo Nordisk also offering $10 billion for the company. Metsera is now weighing rival offers from the two drugmakers.
Analysts note that Pfizer's actions could put it ahead in the bidding war for Metsera. The competition centers around gaining access to Metsera's promising obesity drug assets.
Following reports of Pfizer matching Novo Nordisk's $10 billion bid, shares of Metsera rose sharply.
Metsera is a biotech company that develops drugs to treat obesity.
Both companies want to acquire Metsera to add its promising obesity drug products to their own portfolios.
Pfizer made its offer more attractive to Metsera by removing requirements that could slow down or complicate a potential deal.
Metsera will review the competing offers from Pfizer and Novo Nordisk before deciding which to accept.
Reuters
CNBC Television
Investors Business Daily
Benzinga